PE20040439A1 - Combinacion de compuestos organicos - Google Patents
Combinacion de compuestos organicosInfo
- Publication number
- PE20040439A1 PE20040439A1 PE2003000470A PE2003000470A PE20040439A1 PE 20040439 A1 PE20040439 A1 PE 20040439A1 PE 2003000470 A PE2003000470 A PE 2003000470A PE 2003000470 A PE2003000470 A PE 2003000470A PE 20040439 A1 PE20040439 A1 PE 20040439A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- organic compound
- compound combination
- composition
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229960004064 bumetanide Drugs 0.000 abstract 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- 229960003580 felodipine Drugs 0.000 abstract 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004427 isradipine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38154702P | 2002-05-17 | 2002-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040439A1 true PE20040439A1 (es) | 2004-08-20 |
Family
ID=29550142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000470A PE20040439A1 (es) | 2002-05-17 | 2003-05-15 | Combinacion de compuestos organicos |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20050222137A1 (https=) |
| EP (1) | EP1507529B8 (https=) |
| JP (2) | JP5132872B2 (https=) |
| KR (2) | KR101454070B1 (https=) |
| CN (2) | CN1652777A (https=) |
| AR (1) | AR040014A1 (https=) |
| AT (1) | ATE429223T1 (https=) |
| AU (1) | AU2003240261B2 (https=) |
| BR (1) | BR0310092A (https=) |
| CA (1) | CA2486144C (https=) |
| CY (1) | CY1109240T1 (https=) |
| DE (1) | DE60327316D1 (https=) |
| DK (1) | DK1507529T3 (https=) |
| EC (1) | ECSP045429A (https=) |
| EG (1) | EG24716A (https=) |
| ES (1) | ES2325207T3 (https=) |
| IL (1) | IL164925A (https=) |
| MX (1) | MXPA04011385A (https=) |
| MY (1) | MY138838A (https=) |
| NO (1) | NO333011B1 (https=) |
| NZ (1) | NZ536557A (https=) |
| PE (1) | PE20040439A1 (https=) |
| PL (1) | PL372369A1 (https=) |
| PT (1) | PT1507529E (https=) |
| RU (1) | RU2324482C2 (https=) |
| SI (1) | SI1507529T1 (https=) |
| TW (1) | TWI358291B (https=) |
| WO (1) | WO2003097045A1 (https=) |
| ZA (1) | ZA200408737B (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| KR20120058618A (ko) * | 2003-01-31 | 2012-06-07 | 다이이찌 산쿄 가부시키가이샤 | 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약 |
| EP1628663B1 (en) | 2003-05-15 | 2009-07-29 | Roskamp Research llc | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| WO2004101535A1 (en) * | 2003-05-16 | 2004-11-25 | Novartis Ag | Pharmaceutical composition comprising valsartan |
| JP2009513543A (ja) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロルタリドンの組み合わせ |
| GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
| WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| US20080095841A1 (en) * | 2004-10-06 | 2008-04-24 | Eisai R&D Management Co., Ltd. | Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition |
| ME01615B (me) * | 2004-11-05 | 2014-09-20 | Boehringer Ingelheim Int | Dvoslojna tableta koja sadrži telmisartan i amlodipin |
| CN1830454A (zh) * | 2005-03-10 | 2006-09-13 | 刘智仁 | 盐酸在制备治疗高血压药物中的应用 |
| PL1872783T3 (pl) * | 2005-04-21 | 2012-05-31 | Santen Pharmaceutical Co Ltd | Środek leczniczy w schorzeniach rogówkowo-spojówkowych |
| TWI407978B (zh) * | 2005-06-27 | 2013-09-11 | Sankyo Co | 濕粒狀藥物之製備方法 |
| CA2613417C (en) * | 2005-06-27 | 2011-11-29 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| JP5110697B2 (ja) * | 2005-06-27 | 2012-12-26 | 第一三共株式会社 | 固形製剤 |
| DE102005031577A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20090312311A1 (en) * | 2006-04-06 | 2009-12-17 | Gary Michael Ksander | Combination of organic compounds |
| PE20080991A1 (es) * | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| GB2471970A (en) * | 2006-09-15 | 2011-01-19 | Daiichi Sankyo Co Ltd | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide |
| CN101199848B (zh) * | 2006-11-11 | 2012-05-23 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途 |
| JP5301465B2 (ja) | 2007-01-25 | 2013-09-25 | バーバ・ファーマシューティカルズ・リミテッド | インスリン抵抗性改善薬および治療方法 |
| GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
| NZ584729A (en) | 2007-10-05 | 2012-12-21 | Alzheimer S Inst Of America Inc | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| JP2011507973A (ja) * | 2007-12-31 | 2011-03-10 | ルピン・リミテッド | アムロジピンとバルサルタンとの医薬組成物 |
| CN101564536B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物缓控释制剂 |
| WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| MA33056B1 (fr) | 2009-01-23 | 2012-02-01 | Hanmi Holding Co Ltd | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| WO2011001440A1 (en) * | 2009-07-03 | 2011-01-06 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| RU2425671C1 (ru) * | 2010-06-30 | 2011-08-10 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции нарушений функции почек у больных стабильной стенокардией в сочетании с гипертонической болезнью |
| TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
| GB201116993D0 (en) | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
| KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
| IN2014DN09045A (https=) | 2012-05-07 | 2015-05-22 | Bayer Pharma AG | |
| WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| MX358211B (es) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
| US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
| ES2847904T3 (es) | 2013-07-23 | 2021-08-04 | Daiichi Sankyo Co Ltd | Medicamento para la prevención o el tratamiento de la hipertensión |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| FR3014694B1 (fr) | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| CN104324377B (zh) * | 2014-06-19 | 2017-08-04 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| KR101914930B1 (ko) * | 2015-03-31 | 2018-11-05 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제 |
| CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| CN108778334A (zh) * | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| US10319209B2 (en) | 2016-06-03 | 2019-06-11 | John Carlton-Foss | Method and system for motion analysis and fall prevention |
| KR102912130B1 (ko) * | 2016-11-11 | 2026-01-14 | 주식회사유한양행 | 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법 |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| SI4101454T1 (sl) * | 2017-01-25 | 2024-10-30 | The George Institute for Global Health | Sestavki za uporabo pri zdravljenju hipertenzije |
| FI3658140T3 (fi) * | 2017-02-27 | 2025-08-12 | Idorsia Pharmaceuticals Ltd | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi |
| CN111405899B (zh) | 2017-11-30 | 2025-05-16 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合 |
| AU2019309329B2 (en) * | 2018-07-26 | 2025-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| CN111789843A (zh) | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| AU2021255701B2 (en) * | 2020-04-17 | 2025-12-04 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
| KR102924710B1 (ko) | 2022-07-25 | 2026-02-09 | 안국약품 주식회사 | 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US5350771A (en) * | 1989-03-22 | 1994-09-27 | Peter K. T. Pang | Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers |
| EP0400835A1 (en) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Substituted benzimidazoles as angiotensin II antagonists |
| US5449682A (en) | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
| DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| KR100222252B1 (ko) * | 1990-12-14 | 1999-10-01 | 스튜어트 알. 수터 | 안지오텐신 ii 수용체 차단 조성물 |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5492904A (en) | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| US5260325A (en) | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| US5206348A (en) | 1992-07-23 | 1993-04-27 | Morton International, Inc. | Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same |
| US5266583A (en) | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| US5264447A (en) | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| ATE300287T1 (de) | 1994-02-08 | 2005-08-15 | Novartis Pharma Gmbh | Behandlung von normaldruckglaukom mit valsartan |
| HUT76542A (en) | 1994-03-17 | 1997-09-29 | Ciba Geigy Ag | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
| BR9708336A (pt) | 1996-03-29 | 1999-08-03 | Smithkline Beecham Corp | Diidrato de eprosartan e processo para sua produção e formulação |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US5949290A (en) * | 1997-01-14 | 1999-09-07 | Bertram; Earnest L. | Voltage controlled oscillator tuning apparatus and method |
| JP2002503223A (ja) | 1997-04-11 | 2002-01-29 | アドバンスト・メディシン・インコーポレイテッド | 複数の活性分子を供与する分子 |
| US5991348A (en) * | 1997-08-12 | 1999-11-23 | 3Com Corporation | Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion |
| DE19820151A1 (de) | 1998-05-06 | 1999-11-11 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Candesartan |
| TR200100062T2 (tr) * | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CN1304000C (zh) | 1998-12-23 | 2007-03-14 | 诺瓦提斯公司 | 缬沙坦在制备用于治疗肺癌的药物中的用途 |
| IL144216A0 (en) | 1999-01-26 | 2002-05-23 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating acute myocardial infarction |
| US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CN1301545A (zh) | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
| DE10004651A1 (de) * | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen |
| AR032758A1 (es) | 2000-07-19 | 2003-11-26 | Novartis Ag | Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas |
-
2003
- 2003-05-14 EG EG2003050449A patent/EG24716A/xx active
- 2003-05-15 TW TW092113236A patent/TWI358291B/zh not_active IP Right Cessation
- 2003-05-15 PE PE2003000470A patent/PE20040439A1/es not_active Application Discontinuation
- 2003-05-15 AR ARP030101691A patent/AR040014A1/es unknown
- 2003-05-16 SI SI200331623T patent/SI1507529T1/sl unknown
- 2003-05-16 MY MYPI20031827A patent/MY138838A/en unknown
- 2003-05-16 CA CA2486144A patent/CA2486144C/en not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011385A patent/MXPA04011385A/es active IP Right Grant
- 2003-05-16 BR BR0310092-8A patent/BR0310092A/pt not_active Application Discontinuation
- 2003-05-16 CN CNA038112442A patent/CN1652777A/zh active Pending
- 2003-05-16 KR KR1020117021915A patent/KR101454070B1/ko not_active Expired - Lifetime
- 2003-05-16 AT AT03732397T patent/ATE429223T1/de active
- 2003-05-16 PL PL03372369A patent/PL372369A1/xx not_active Application Discontinuation
- 2003-05-16 KR KR10-2004-7018461A patent/KR20050000546A/ko not_active Ceased
- 2003-05-16 US US10/514,682 patent/US20050222137A1/en not_active Abandoned
- 2003-05-16 DE DE60327316T patent/DE60327316D1/de not_active Expired - Lifetime
- 2003-05-16 RU RU2004137105/15A patent/RU2324482C2/ru not_active IP Right Cessation
- 2003-05-16 DK DK03732397T patent/DK1507529T3/da active
- 2003-05-16 NZ NZ536557A patent/NZ536557A/en not_active IP Right Cessation
- 2003-05-16 AU AU2003240261A patent/AU2003240261B2/en not_active Expired
- 2003-05-16 JP JP2004505044A patent/JP5132872B2/ja not_active Expired - Lifetime
- 2003-05-16 PT PT03732397T patent/PT1507529E/pt unknown
- 2003-05-16 CN CN2009102075232A patent/CN101890166A/zh active Pending
- 2003-05-16 ES ES03732397T patent/ES2325207T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/005180 patent/WO2003097045A1/en not_active Ceased
- 2003-05-16 EP EP03732397A patent/EP1507529B8/en not_active Revoked
-
2004
- 2004-10-28 IL IL164925A patent/IL164925A/en unknown
- 2004-10-28 ZA ZA200408737A patent/ZA200408737B/en unknown
- 2004-11-12 EC EC2004005429A patent/ECSP045429A/es unknown
- 2004-12-13 NO NO20045429A patent/NO333011B1/no not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/338,066 patent/US8101599B2/en not_active Expired - Fee Related
-
2009
- 2009-07-14 CY CY20091100746T patent/CY1109240T1/el unknown
-
2010
- 2010-07-02 JP JP2010152053A patent/JP2010209123A/ja active Pending
-
2012
- 2012-01-12 US US13/348,833 patent/US20120115854A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040439A1 (es) | Combinacion de compuestos organicos | |
| JP5148296B2 (ja) | アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物 | |
| JP5110697B2 (ja) | 固形製剤 | |
| JP5063370B2 (ja) | 湿式造粒製薬の調製方法 | |
| PE20070803A1 (es) | Combinacion farmaceutica de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra | |
| RU2019126749A (ru) | Композиции для лечения гипертензии | |
| PE20050464A1 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| PE107099A1 (es) | Composicion de atorvastatina y un antihipertensor | |
| PE20010940A1 (es) | Composiciones de valdecoxib | |
| CL2004000643A1 (es) | Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. | |
| JP2005533023A5 (https=) | ||
| EP1575566A4 (en) | MULTILAYER DOSAGE FORMS WITH NSAIDS AND TRIPTANES | |
| RU2010118022A (ru) | Фармацевтическая композиция валсартана | |
| EP1750862A2 (en) | Pharmaceutical composition containing irbesartan | |
| TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
| JP2020506180A5 (https=) | ||
| PE20000066A1 (es) | Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion | |
| BR0111868A (pt) | Composições farmacêuticas | |
| HRP20120134T1 (hr) | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem | |
| WO2004108084A3 (en) | Polymorphic forms of naltrexone | |
| EP1549655A4 (en) | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS | |
| ATE390148T1 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| PE20050252A1 (es) | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+ | |
| BRPI0503775A (pt) | composição que compreende um amido parcialmente pré-gelatinizado e método de preparar o mesmo | |
| PE20011316A1 (es) | Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |